Taeho Greg Rhee1, Joseph S Ross2, Robert A Rosenheck3, Lauretta E Grau4, David A Fiellin5, William C Becker6. 1. Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, CT, United States; Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, United States; Mental Illness Research, Education and Clinical Center of New England, US Department of Veterans Affairs Connecticut Healthcare System, West Haven, CT, United States; Yale Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, United States. Electronic address: tgrhee.research@gmail.com. 2. Yale Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, United States; Section of General Internal Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States; Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, United States. 3. Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, United States; Mental Illness Research, Education and Clinical Center of New England, US Department of Veterans Affairs Connecticut Healthcare System, West Haven, CT, United States; Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, United States. 4. Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, CT, United States. 5. Section of General Internal Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States; Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, United States. 6. Section of General Internal Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States; Pain Research, Informatics, Multi-morbidities and Education Center of Excellence, VA Connecticut Healthcare System, West Haven, CT, United States.
Abstract
OBJECTIVES: To examine trends in polysubstance detection associated with drug-related overdose deaths in Connecticut. METHODS: We used 2012-2018 data provided by Connecticut's Office of the Chief Medical Examiner (OCME) on accidental overdose deaths. We estimated annual trends, standardizing the number of deaths per 100,000 Connecticut residents each year. We then conducted stratified analyses by polysubstance use status. We also examined the numbers of deaths involving fentanyl in a separate analysis. We obtained data in April 2019, and statistical analyses were performed from April to September 2019. RESULTS: The rate of overdose deaths in Connecticut increased from 9.9 per 100,000 residents in 2012 to 28.5 per 100,000 residents in 2018-a 221 % increase-with the majority occurring among persons aged 35-64 (65.3 %), men (73.9 %), and non-Hispanic whites (78.5 %). Among deaths involving fentanyl, the overall deaths escalated from 5.2 deaths per 100,000 residents in 2015 to 21.3 deaths per 100,000 residents in 2018, and more than 50% of these fentanyl-related deaths involved polysubstance use. CONCLUSIONS: Connecticut experienced a more-than doubling of opioid-involved overdose deaths, largely driven by fentanyl and polysubstance use. The role of polysubstance use should be considered in efforts toward reducing opioid-related overdose incidents.
OBJECTIVES: To examine trends in polysubstance detection associated with drug-related overdose deaths in Connecticut. METHODS: We used 2012-2018 data provided by Connecticut's Office of the Chief Medical Examiner (OCME) on accidental overdose deaths. We estimated annual trends, standardizing the number of deaths per 100,000 Connecticut residents each year. We then conducted stratified analyses by polysubstance use status. We also examined the numbers of deaths involving fentanyl in a separate analysis. We obtained data in April 2019, and statistical analyses were performed from April to September 2019. RESULTS: The rate of overdose deaths in Connecticut increased from 9.9 per 100,000 residents in 2012 to 28.5 per 100,000 residents in 2018-a 221 % increase-with the majority occurring among persons aged 35-64 (65.3 %), men (73.9 %), and non-Hispanic whites (78.5 %). Among deaths involving fentanyl, the overall deaths escalated from 5.2 deaths per 100,000 residents in 2015 to 21.3 deaths per 100,000 residents in 2018, and more than 50% of these fentanyl-related deaths involved polysubstance use. CONCLUSIONS: Connecticut experienced a more-than doubling of opioid-involved overdose deaths, largely driven by fentanyl and polysubstance use. The role of polysubstance use should be considered in efforts toward reducing opioid-related overdose incidents.
Authors: Mary C Figgatt; Anna E Austin; Mary E Cox; Scott Proescholdbell; Stephen W Marshall; Rebecca B Naumann Journal: Drug Alcohol Depend Date: 2021-01-02 Impact factor: 4.492
Authors: Sarah Konefal; Adam Sherk; Bridget Maloney-Hall; Matthew Young; Pam Kent; Emily Biggar Journal: BMC Public Health Date: 2022-02-10 Impact factor: 3.295
Authors: Ju Nyeong Park; Kristin E Schneider; David Fowler; Susan G Sherman; Ramin Mojtabai; Paul S Nestadt Journal: J Addict Med Date: 2022 Jan-Feb 01 Impact factor: 3.702